伊立替康单药和联合沙利度胺治疗铂类耐药卵巢癌疗效比较观察  

Thalidomide plus irinotecan compared with irinotecan alone in treatment of patients with platinum-resistant ovarian cancer

作　　者：苏安[1] 潘战和[1] 张靖[1] 王馨[1] 吕霞[1] 肖莉[1] 王琳[1] 

机构地区：[1]厦门大学附属中山医院肿瘤科,厦门361004

出　　处：《中华肿瘤防治杂志》2009年第7期553-554,560,共3页Chinese Journal of Cancer Prevention and Treatment

摘　　要：为了比较沙利度胺加伊立替康与伊立替康单药治疗铂类耐药卵巢癌的疗效与毒性,对入选的38例患者分为沙利度胺组18例,接受伊立替康125mg/m2,d1、d8,每21d为1个周期,加沙利度胺100mg/d起步,逐渐加至200mg/d;对照组20例单用伊立替康。结果:38例患者可评估,沙利度胺组和对照组的客观有效率分别为27.8%和15.0%;疾病控制率分别为61.1%和35.0%;疾病进展时间分别为4.6和3.1个月;中位生存时间分别为13和10个月。初步研究结果提示,沙利度胺加伊立替康对比伊立替康单药治疗铂类耐药卵巢癌有更好的临床疗效,值得进一步进行临床试验。The objective of this study was to compare the efficacy and toxicity of thalidomide plus irinotecan versus irinotecan alone in the treatment of patients with platinum-resistant ovarian cancer. Thirty eight patients were eligible for this study. Eighteen patients in the thalidomide group received irinotecan at a close of 125 mg/m^2 on Day 1 and day 8 of a 21-day cycle with thalidomide starting at a dose of 100 mg per day and then increasing the dose to 200 mg per day. Twenty patients in the control group received irinoteean alone. Results： The analysis included the 38 patients. The overall response rate in the control group was 15.0% compared with 27.8% in the thalidomide group. The disease control rate in the control group was 35.0% compared with 61.1 % in the thalidomide group. The median progression-free survival for the control group was 3.1 months compared with 4.6 months in the thalidomide group. The median overall survival was 10 months in the control arm and 13 months in the thalidomide group. The results of this pilot study suggest that the treatment with thalidomide plus irinotecan results in clinically better efficacy outcomes compared with irinoteean alone in patients with platinum resistant ovarian cancer. Additional clinical trials are warranted.

关 键 词：卵巢肿瘤/药物疗法 沙利度胺 伊立替康 药物疗法 联合 

分 类 号：R737.31[医药卫生—肿瘤]